



IFW
CASE PH-7497 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Eileen M. Immordino

Type or print name

Signature

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

SMALLHEER ET AL.

APPLICATION NO: 10/824,025

FILED: APRIL 14, 2004

FOR: BIARYLMETHYL INDOLINES, INDOLES AND
TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE
INHIBITORS

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Jing S. Belfield
Agent for Applicants
Reg. No. 45,914

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791

Date:

INFORMATION DISCLOSURE CITATION



(Use several sheets if necessary)

ATTY. DOCKET NO.
PH-7497 NP
APPLICATION NO.
10/824,025
APPLICANT
SMALLHEER ET AL.
FILING DATE
APRIL 14, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM							<input type="checkbox"/>	<input type="checkbox"/>
AN							<input type="checkbox"/>	<input type="checkbox"/>
AO							<input type="checkbox"/>	<input type="checkbox"/>
AP							<input type="checkbox"/>	<input type="checkbox"/>
AQ							<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Walsh, P.N., "Platelets and Factor XI Bypass the Contact System of Blood Coagulation", <i>Thromb. Haemostasis</i> . 82(2), pp. 234-242, 1999.
AS	Coleman, R. Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive, and Antiangiogenic Activities", <i>Hemostasis and thrombosis: basic principles and clinical practice</i> , Lippincott Williams & Wilkins, 2001, pp. 103-122.
AT	Schmaier, A.H., "Contact Activation", <i>Thrombosis and Hemorrhage</i> , Williams & Wilkins, 1998, pp. 105-128.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**FORM PTO-1449
(REV. 7-85)**

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PH-7497 NP
APPLICATION NO.
10/824,025
APPLICANT
SMALLHEER ET AL.
FILING DATE
APRIL 14, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

EXAMINER

DATE CONSIDERED

***EXAMINER:** Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PH-7497 NP
APPLICATION NO.
10/824,025
APPLICANT
SMALLHEER ET AL.
FILING DATE
APRIL 14, 2004

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Walsh, P.N., "Platelets and Factor XI Bypass the Contact System of Blood Coagulation", <i>Thromb. Haemostasis</i> . 82(2), pp. 234-242, 1999.
AS	Coleman, R. Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive, and Antiangiogenic Activities", <i>Hemostasis and thrombosis: basic principles and clinical practice</i> , Lippincott Williams & Wilkins, 2001, pp. 103-122.
AT	Schmaier, A.H., "Contact Activation", <i>Thrombosis and Hemorrhage</i> , Williams & Wilkins, 1998, pp. 105-128.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
PH-7497 NP
APPLICATION NO.
10/824,025
APPLICANT
SMALLHEER ET AL.
FILING DATE
APRIL 14, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AU	Galiani, D., "Activation of Factor IX by Factor Xla", <i>Trends in Cardiovascular Medicine</i> , Vol. 10, No. 5, 2000, pp. 198-204
AV	Bouma, B.N. et al., "Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)", <i>Thrombosis. Research</i> , 2001, 101, pp. 329-354
AW	Gailani, D., "Gene Targeting in Hemostasis. Factor XI", <i>Frontiers in Bioscience</i> , 2001, 6, pp. d201-d207
AX	Gailani, D., et al., "A murine model of factor XI deficiency", <i>Blood Coagulation and Fibrinolysis</i> , 1997, Vol. 8, pp. 134-144
AY	Minnema, M.C., et al., "Activation of Clotting Factors XI and IX in Patients with Acute Myocardial Infarction", <i>Arterioscler. Thromb. Vasc. Biol.</i> , 2000, 20, pp. 2489-2493
AZ	Murakami, T., et al., "Evaluation of Factor Xla- α_1 -Antitrypsin in Plasma, a Contact Phase-Activated Coagulation Factor-Inhibitor Complex, in Patients With Coronary Artery Disease", <i>Arterioscler. Thromb. Vasc. Biol.</i> , 1995, 15, pp. 1107-1113
2AA	Meijers, J.C.M., et al., "High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis", <i>N. Engl. J. Med.</i> , 2000, Vol. 342, No. 10, pp. 696-701
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.